Entyvio

Entyvio is the brand name of vedolizumab, a humanized monoclonal antibody used to treat inflammatory bowel disease. It targets the gut-specific integrin α4β7 on activated T lymphocytes, inhibiting their interaction with MAdCAM-1 on intestinal blood vessels. This reduces lymphocyte trafficking to the gut and decreases mucosal inflammation, offering a gut-selective approach to therapy.

Indications and history: Vedolizumab is approved for adults with moderately to severely active Crohn's disease or ulcerative colitis who have had an inadequate response to, or intolerance of, conventional therapy or TNF inhibitors. It was approved by the U.S. FDA in 2014 and subsequently by major regulatory bodies in Europe and other regions. Pediatric indications have been developed in some jurisdictions for children aged 6 years and older.

Dosing and administration: The drug is given by intravenous infusion at a dose of 300 mg on weeks 0, 2, and 6, followed by every 8 weeks thereafter. Infusions typically last about 30 minutes. Patients should be monitored for infusion-related reactions during and after administration. Dosing may be adjusted only under specialist supervision and discontinuation considered if inadequate response during the induction/early maintenance phase.

Safety and adverse effects: Common adverse effects include headaches, nasopharyngitis, nausea, and arthralgia. Infusion reactions can occur. Vedolizumab carries a risk of infections, and patients should be vaccinated according to guidelines before starting therapy. Hypersensitivity reactions and rare immunogenic responses have been reported. As with other biologics, careful monitoring for malignancy is advised during long-term use. It is contraindicated in individuals with a known hypersensitivity to vedolizumab or any component of the formulation.

Manufacturer: Entyvio is marketed by Takeda.